What is HC Wainwright’s Forecast for Oculis Q1 Earnings?

Oculis Holding AG (NASDAQ:OCS) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Oculis in a report released on Monday, May 12th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.40) EPS.

Several other analysts have also issued reports on the company. Chardan Capital increased their price objective on Oculis from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Robert W. Baird raised their price target on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th.

Oculis Price Performance

NASDAQ OCS opened at $17.76 on Tuesday. The company has a 50 day simple moving average of $17.99 and a 200-day simple moving average of $18.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. Oculis has a 52-week low of $10.79 and a 52-week high of $23.08. The firm has a market capitalization of $775.44 million, a price-to-earnings ratio of -9.20 and a beta of 0.27.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million.

Institutional Trading of Oculis

Several large investors have recently made changes to their positions in OCS. Bellevue Group AG acquired a new position in Oculis in the 4th quarter valued at $170,000. XTX Topco Ltd acquired a new stake in shares of Oculis in the fourth quarter worth $225,000. Kestra Private Wealth Services LLC acquired a new position in Oculis during the 1st quarter valued at $234,000. Geode Capital Management LLC boosted its holdings in Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in Oculis in the 4th quarter worth $389,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.